NO319250B1 - Paramunitetinducer basert pa poxviruskomponenter, fremgangsmate for fremstilling derav og anvendelse som farmasoytiske sammensetninger. - Google Patents

Paramunitetinducer basert pa poxviruskomponenter, fremgangsmate for fremstilling derav og anvendelse som farmasoytiske sammensetninger. Download PDF

Info

Publication number: NO319250B1
Authority: NO; Norway
Prior art keywords: paraimmunity; poxvirus; poxviruses; virus; components
Prior art date: 1994-02-23

Application number

NO19963462A

Other languages

English (en)

Norwegian (no)

Other versions

NO963462L (no

Inventor

Anton Mayr

Original Assignee

Anton Mayr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-23

Filing date

1996-08-20

Publication date

2005-07-04

1996-08-20 Application filed by Anton Mayr filed Critical Anton Mayr

1996-08-20 Publication of NO963462L publication Critical patent/NO963462L/no

2005-07-04 Publication of NO319250B1 publication Critical patent/NO319250B1/no

Links

239000000411 inducer Substances 0.000 title claims abstract description 74
238000000034 method Methods 0.000 title claims abstract description 52
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
230000008569 process Effects 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title description 22
241000700605 Viruses Species 0.000 claims description 55
230000002238 attenuated effect Effects 0.000 claims description 38
230000003612 virological effect Effects 0.000 claims description 28
229920001184 polypeptide Polymers 0.000 claims description 26
102000004196 processed proteins & peptides Human genes 0.000 claims description 26
108090000765 processed proteins & peptides Proteins 0.000 claims description 26
241000700639 Parapoxvirus Species 0.000 claims description 20
241000700663 Avipoxvirus Species 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 15
241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 11
241000178270 Canarypox virus Species 0.000 claims description 10
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 9
108010067390 Viral Proteins Proteins 0.000 claims description 6
230000000984 immunochemical effect Effects 0.000 claims description 5
230000000694 effects Effects 0.000 abstract description 36
239000003814 drug Substances 0.000 abstract description 12
229940079593 drug Drugs 0.000 abstract description 7
210000004027 cell Anatomy 0.000 description 31
108090000623 proteins and genes Proteins 0.000 description 29
238000012360 testing method Methods 0.000 description 26
238000004113 cell culture Methods 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 21
208000015181 infectious disease Diseases 0.000 description 20
235000018102 proteins Nutrition 0.000 description 18
239000000725 suspension Substances 0.000 description 18
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
230000003053 immunization Effects 0.000 description 9
230000002779 inactivation Effects 0.000 description 9
230000002458 infectious effect Effects 0.000 description 9
239000002609 medium Substances 0.000 description 9
241000894007 species Species 0.000 description 9
241000287828 Gallus gallus Species 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
235000013330 chicken meat Nutrition 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
239000000463 material Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
101710172711 Structural protein Proteins 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
239000000499 gel Substances 0.000 description 7
238000002649 immunization Methods 0.000 description 7
102000014150 Interferons Human genes 0.000 description 6
108010050904 Interferons Proteins 0.000 description 6
230000036039 immunity Effects 0.000 description 6
238000002156 mixing Methods 0.000 description 6
239000002245 particle Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
241000700618 Vaccinia virus Species 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000011081 inoculation Methods 0.000 description 5
229940079322 interferon Drugs 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
210000001161 mammalian embryo Anatomy 0.000 description 5
230000007017 scission Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000013598 vector Substances 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
235000019687 Lamb Nutrition 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000011109 contamination Methods 0.000 description 4
230000007123 defense Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
210000002257 embryonic structure Anatomy 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
210000003292 kidney cell Anatomy 0.000 description 4
239000010410 layer Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
239000000047 product Substances 0.000 description 4
230000000644 propagated effect Effects 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
210000003501 vero cell Anatomy 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
241000233866 Fungi Species 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
241001467552 Mycobacterium bovis BCG Species 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
241000700647 Variola virus Species 0.000 description 3
230000009471 action Effects 0.000 description 3
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000002281 colonystimulating effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000036512 infertility Effects 0.000 description 3
229940047122 interleukins Drugs 0.000 description 3
238000011835 investigation Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
210000002433 mononuclear leukocyte Anatomy 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
102000003390 tumor necrosis factor Human genes 0.000 description 3
210000001835 viscera Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
241000271566 Aves Species 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 2
241000186216 Corynebacterium Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010019973 Herpes virus infection Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000004407 Lactalbumin Human genes 0.000 description 2
108090000942 Lactalbumin Proteins 0.000 description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000000721 bacterilogical effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000000432 density-gradient centrifugation Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960001614 levamisole Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000010998 test method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
PUMRUSBKNSBTAL-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-2-carbaldehyde Chemical compound C1=CC=C2OC(C=O)CCC2=C1 PUMRUSBKNSBTAL-UHFFFAOYSA-N 0.000 description 1
-1 CSF Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
241000186427 Cutibacterium acnes Species 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
101000653281 Enterobacteria phage T4 Uncharacterized 11.1 kDa protein in Gp30-rIII intergenic region Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
241001295925 Gegenes Species 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
101001083288 Methanococcus vannielii 50S ribosomal protein L32e Proteins 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010061308 Neonatal infection Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000700635 Orf virus Species 0.000 description 1
241000283898 Ovis Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241001455645 Rabbitpox virus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000287231 Serinus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043275 Teratogenicity Diseases 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
208000032159 Vaginal inflammation Diseases 0.000 description 1
206010048937 Vaginal lesion Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
201000005332 contagious pustular dermatitis Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000000280 densification Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
244000144972 livestock Species 0.000 description 1
235000020121 low-fat milk Nutrition 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
229940055019 propionibacterium acne Drugs 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
208000037921 secondary disease Diseases 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
108010013480 succinylated gelatin Proteins 0.000 description 1
229940007079 succinylated gelatin Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000000576 supplementary effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
231100000211 teratogenicity Toxicity 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
239000011800 void material Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19963462A 1994-02-23 1996-08-20 Paramunitetinducer basert pa poxviruskomponenter, fremgangsmate for fremstilling derav og anvendelse som farmasoytiske sammensetninger. NO319250B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4405841A DE4405841C1 (de)	1994-02-23	1994-02-23	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP1995/000160 WO1995022978A1 (fr)	1994-02-23	1995-01-17	Inducteur de para-immunite base sur des combinaisons de constituants de poxvirus, son procede de preparation et son utilisation en tant que medicament

Publications (2)

Publication Number	Publication Date
NO963462L NO963462L (no)	1996-08-20
NO319250B1 true NO319250B1 (no)	2005-07-04

Family

ID=6511005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19963462A NO319250B1 (no)	1994-02-23	1996-08-20	Paramunitetinducer basert pa poxviruskomponenter, fremgangsmate for fremstilling derav og anvendelse som farmasoytiske sammensetninger.

Country Status (20)

Country	Link
US (1)	US6805870B1 (fr)
EP (1)	EP0669133B1 (fr)
JP (1)	JP2873880B2 (fr)
KR (1)	KR100196204B1 (fr)
CN (1)	CN1142187A (fr)
AT (1)	ATE153242T1 (fr)
AU (1)	AU690625B2 (fr)
BR (1)	BR9506882A (fr)
CA (1)	CA2182207C (fr)
DE (2)	DE4405841C1 (fr)
DK (1)	DK0669133T3 (fr)
ES (1)	ES2102081T3 (fr)
FI (1)	FI116557B (fr)
GR (1)	GR3023508T3 (fr)
HU (1)	HU220972B1 (fr)
NO (1)	NO319250B1 (fr)
NZ (1)	NZ278079A (fr)
PL (1)	PL182132B1 (fr)
SI (1)	SI0669133T1 (fr)
WO (1)	WO1995022978A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2103991C1 (ru) *	1995-08-14	1998-02-10	Научно-производственное объединение "Иммунопрепарат"	Средство для лечения стрептококковых заболеваний
CA2247336C (fr) *	1996-02-28	2008-06-17	Bayer Aktiengesellschaft	Parapoxvirus contenant de l'adn etranger, leur production et leur utilisation dans des vaccins
DK0885013T3 (da) *	1996-04-15	2001-11-05	Anton Prof Dr Med Vet Dr Mayr	Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler
JPH1192390A (ja) *	1997-09-17	1999-04-06	Natl Fedelation Of Agricult Coop Assoc	ストレス状態改善剤
CA2335508A1 (fr) *	1998-06-26	2000-01-06	Aventis Pasteur	Utilisation de poxvirus en tant que renforcateurs d'immunite specifique
DE19922407A1 (de) *	1999-05-14	2000-11-16	Bayer Ag	Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
ATE412762T1 (de) *	1999-05-28	2008-11-15	Helmholtz Zentrum Muenchen	Vektor zur integration von heterologen sequenzen in poxvirusgenomen
CN1291012C (zh)	2000-03-14	2006-12-20	巴法里安诺迪克有限公司	修饰的安卡拉牛痘病毒(mva)的变株
RU2003104522A (ru)	2000-07-11	2004-06-27	Байер Акциенгезельшафт (De)	Применение штаммов parapoxvirus (парапокс-вируса) против органофиброзов
DE10122233A1 (de) *	2000-07-11	2002-01-24	Bayer Ag	Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
GB2381454B8 (en) *	2000-07-11	2007-10-23	Aicuris Gmbh & Co Kg	Use of strains of Parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
DE10122451A1 (de) *	2000-07-11	2002-04-04	Bayer Ag	Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
US7445924B2 (en)	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en)	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) *	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
PL212047B1 (pl) *	2000-11-23	2012-08-31	Bavarian Nordic As	Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
UA82466C2 (uk) *	2001-07-18	2008-04-25	Бавариан Нордика А/С	Спосіб посилення ампліфікації хордопоксвірусу
EP2345665A3 (fr)	2001-12-04	2012-02-15	Bavarian Nordic A/S	Le vaccin de sous-unité de NS1 de Flavivirus
US6844000B2 (en)	2001-12-07	2005-01-18	Bayer Pharmaceuticals Corporation	Use of Parapox B2L protein to treat cancer and modify immune responses
US6723329B2 (en) *	2001-12-07	2004-04-20	Board Of Regents, The University Of Texas System	Use of parapox B2L protein to modify immune responses to administered antigens
US6752995B2 (en) *	2002-04-15	2004-06-22	Board Of Regents, The University Of Texas System	Nucleic acid and polypeptide sequences useful as adjuvants
NZ536592A (en) *	2002-04-19	2007-01-26	Bavarian Nordic As	Modified vaccinia virus ankara for the vaccination of neonates
JP2005537793A (ja)	2002-09-05	2005-12-15	バヴァリアン・ノルディック・アクティーゼルスカブ	無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
DE102004003572A1 (de)	2004-01-23	2005-08-18	Bavarian Nordic A/S	Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
CA2573204C (fr) *	2004-07-13	2011-09-20	Aicuris Gmbh & Co. Kg	Parapoxvirus combines a d'autres agents antiviraux dans le traitement du vih/sida
DE102004046391A1 (de) *	2004-09-24	2006-04-06	Bioveta Ag	Neuer Impfstoff für veterinäre und humanmedizinische Prophylaxe und Therapie
DE102005027956B4 (de) *	2005-06-16	2009-10-22	Mayr, Anton, Prof. Dr. Dr. h.c. mult.	Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen
US20140255447A1 (en) *	2013-03-05	2014-09-11	Biomune Company	Production of avian embryo cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3816139A1 (de) *	1987-10-17	1989-04-27	Bayer Ag	Verfahren zur herstellung von paramunitaetsinducern

1994
- 1994-02-23 DE DE4405841A patent/DE4405841C1/de not_active Expired - Fee Related
- 1994-03-01 AT AT94103047T patent/ATE153242T1/de not_active IP Right Cessation
- 1994-03-01 EP EP94103047A patent/EP0669133B1/fr not_active Expired - Lifetime
- 1994-03-01 SI SI9430051T patent/SI0669133T1/xx unknown
- 1994-03-01 DK DK94103047.0T patent/DK0669133T3/da active
- 1994-03-01 DE DE59402826T patent/DE59402826D1/de not_active Expired - Fee Related
- 1994-03-01 ES ES94103047T patent/ES2102081T3/es not_active Expired - Lifetime
1995
- 1995-01-17 BR BR9506882A patent/BR9506882A/pt not_active Application Discontinuation
- 1995-01-17 US US08/693,052 patent/US6805870B1/en not_active Expired - Fee Related
- 1995-01-17 KR KR1019960704653A patent/KR100196204B1/ko not_active Expired - Fee Related
- 1995-01-17 CN CN95191784A patent/CN1142187A/zh active Pending
- 1995-01-17 JP JP7522088A patent/JP2873880B2/ja not_active Expired - Fee Related
- 1995-01-17 NZ NZ278079A patent/NZ278079A/en unknown
- 1995-01-17 PL PL95316024A patent/PL182132B1/pl not_active IP Right Cessation
- 1995-01-17 AU AU14167/95A patent/AU690625B2/en not_active Ceased
- 1995-01-17 CA CA002182207A patent/CA2182207C/fr not_active Expired - Fee Related
- 1995-01-17 WO PCT/EP1995/000160 patent/WO1995022978A1/fr not_active Ceased
- 1995-01-17 HU HU9601947A patent/HU220972B1/hu not_active IP Right Cessation
1996
- 1996-08-20 NO NO19963462A patent/NO319250B1/no unknown
- 1996-08-22 FI FI963277A patent/FI116557B/fi not_active IP Right Cessation
1997
- 1997-05-22 GR GR960403502T patent/GR3023508T3/el unknown

Also Published As

Publication number	Publication date
BR9506882A (pt)	1997-08-19
US6805870B1 (en)	2004-10-19
ES2102081T3 (es)	1997-07-16
KR100196204B1 (ko)	1999-06-15
HUT75545A (en)	1997-05-28
EP0669133B1 (fr)	1997-05-21
FI963277L (fi)	1996-08-22
AU690625B2 (en)	1998-04-30
JPH09504803A (ja)	1997-05-13
DE59402826D1 (de)	1997-06-26
AU1416795A (en)	1995-09-11
CN1142187A (zh)	1997-02-05
HU9601947D0 (en)	1996-09-30
PL316024A1 (en)	1996-12-23
HU220972B1 (hu)	2002-07-29
ATE153242T1 (de)	1997-06-15
CA2182207A1 (fr)	1995-08-31
WO1995022978A1 (fr)	1995-08-31
SI0669133T1 (en)	1997-10-31
FI116557B (fi)	2005-12-30
CA2182207C (fr)	2000-02-29
NZ278079A (en)	1998-01-26
NO963462L (no)	1996-08-20
EP0669133A1 (fr)	1995-08-30
FI963277A0 (fi)	1996-08-22
DE4405841C1 (de)	1995-01-05
PL182132B1 (pl)	2001-11-30
GR3023508T3 (en)	1997-08-29
JP2873880B2 (ja)	1999-03-24
DK0669133T3 (da)	1997-07-14
KR970701062A (ko)	1997-03-17

Legal Events

Date	Code	Title	Description
2005-10-24	CREP	Change of representative	Representative=s name: ZACCO NORWAY AS POSTBOKS 2003 VIKA OSLO, 0125 NO

Publication	Publication Date	Title
NO319250B1 (no)	2005-07-04	Paramunitetinducer basert pa poxviruskomponenter, fremgangsmate for fremstilling derav og anvendelse som farmasoytiske sammensetninger.
JP7391831B2 (ja)	2023-12-05	Ｃａｒｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用
KR20030032928A (ko)	2003-04-26	변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
JP2000500115A (ja)	2000-01-11	組換え体ポックスウイルス−狂犬病組成物および組合せ組成物並びに使用
CN109136198B (zh)	2021-04-13	一种表达鸡传染性贫血病毒vp1、vp2基因重组鸡痘病毒活载体疫苗
JP4700907B2 (ja)	2011-06-15	ウイルス増殖方法
RU2697151C2 (ru)	2019-08-12	Рекомбинантный нокаутный мутант вируса нодулярного дерматита и его применение
US6942855B2 (en)	2005-09-13	Viral vectors having reduced virulence
AU2009201629B2 (en)	2011-06-02	Production of ALVAC on avian embryonic stem cells
JPH11509099A (ja)	1999-08-17	マレック病ウイルス遺伝子およびマレック病に対する防御のためのワクチンにおけるそれらの使用
JP2781605B2 (ja)	1998-07-30	組み換えアビポックスウイルス
IL176634A (en)	2011-03-31	Monoparamunity inducers based on attenuated rabbit myxoma viruses
CA2610277A1 (fr)	2006-12-21	Souches de poxvirus fortement attenuees, procede pour les produire et leur utilisation pour induire la paramunite, ou pour preparer des vaccins a vecteur
Kim et al.	2010	Marek’s disease viruses lacking either R-LORF10 or LORF4 have altered virulence in chickens
CN107245105A (zh)	2017-10-13	HN‑VP233‑221aa融合蛋白及其制备方法和应用
JP3924328B2 (ja)	2007-06-06	新規ｄｎａベクター、及び組み換え新規ｄｎａベクターを有効成分とするワクチン
EP0953642B1 (fr)	2005-12-28	Proteine antigenique tirant son origine du virus de la laryngo-tracheite infectieuse
JPH09271383A (ja)	1997-10-21	組み換えウイルス、その作製法およびその利用
JPWO1998044093A1 (ja)	2000-09-05	新規ｄｎａベクター、及び組み換え新規ｄｎａベクターを有効成分とするワクチン